Search

Bone marrow transplantation is performed for an increasing number of disorders. Although much has been written about blood transfusion in bone marrow recipients, there is little information dealing with blood transfusion in bone marrow donors. We examined the records of 129 consecutive allogeneic bone marrow transplants to determine blood use by bone marrow donors. We attempted to correlate blood transfusion requirements with a number of variables in both donors and recipients of bone marrow. The volume of marrow harvested correlated closely with the number of units of blood transfused (r = 0.82). When these two variables were expressed as a percent of estimated blood volume, the correlation improved slightly (r = 0.85). Although the volume of marrow correlated highly with the total number of mononuclear cells harvested (r = 0.92), the correlation between total cells harvested and number of units of blood transfused was not as high (r = 0.75). By knowing the number of marrow cells the recipient requires for transplantation, the volume of donor marrow required and donor blood transfusion requirements can be estimated. In most instances, autologous blood could be used exclusively, thus eliminating the risks associated with homologous blood transfusion.

Iontophoretic application of tobramycin was used to deliver drug to the cornea of rabbit eyes infected with a tobramycin-resistant strain of Pseudomonas aeruginosa (MIC = 31.25 micrograms/ml). Corneas infected with P. aeruginosa 27853/pMG6 were treated 22 hours after infection with tobramycin delivered by either iontophoresis, mock iontophoresis (eye cup without current), or application of fortified topical drops. Corneal iontophoresis of tobramycin at 25 mg/ml caused more than a three log reduction in bacteria; yielding a significantly lower number of bacteria compared to untreated controls and all other treatments (P less than or equal to 0.0001). Corneal iontophoresis of tobramycin at 10 mg/ml showed a one log reduction in the number of bacteria per cornea, yielding a significantly lower number of bacteria compared to untreated controls (P less than or equal to 0.0001), corneas treated with nine topical applications of 1.36% tobramycin drops (P less than or equal to 0.0001), and corneas treated with mock iontophoresis (P less than or equal to 0.02). These results suggest that iontophoresis is a powerful ocular delivery system for tobramycin and may be suitable for use with other chemotherapeutic agents.

Intraocular pressure measurements with the Goldmann and Schiotz tonometers are unreliable when the cornea is irregular due to disease or surgery. The Tono-Pen (Oculab, Glendale, Calif) is an electronic applanation tonometer based on the same principle as the MacKay-Marg tonometer. We measured intraocular pressure in 37 eyes with irregular corneas, in 50 eyes that had recently undergone penetrating keratoplasty, in 16 eyes that had undergone epikeratophakia, and in 12 eyes with normal corneas with both the MacKay-Marg and Tono-Pen tonometers. The same two instruments were used, and the sequence of measurement was randomized. Analysis of variance demonstrated no significant difference between measurements obtained with the two tonometers in any of the groups. The data suggest that the Tono-Pen is as accurate as the MacKay-Marg tonometer in those situations where the Goldmann tonometer is inaccurate.

Collagen shields made of porcine collagen were placed in a solution containing tobramycin sulfate (40 or 200 mg/ml) for five minutes, then applied to rabbit eyes. One, four, or eight hours after application, the corneas, aqueous humor samples, and shields were assayed for antibiotic. At all intervals, the concentration of antibiotic in the corneas and aqueous humor samples exceeded the mean inhibitory concentration for tobramycin, as determined for most strains of Pseudomonas. Shields immersed in 200 mg/ml tobramycin produced significantly higher concentrations of antibiotic in the cornea at one hour than subconjunctival injections of tobramycin (20 mg) (P = .0001). Shields immersed in 40 mg/ml tobramycin produced higher, although not significantly higher, concentrations of antibiotic in the cornea at one hour than subconjunctival injections of tobramycin (20 mg) (P = .318). Shields immersed in commercially available tobramycin drops or injectable tobramycin solution (40 mg/ml) caused no epithelial damage visible by slitlamp examination. Collagen shields containing antibiotics can serve as a vehicle for drug delivery and may prove superior to current methods for preoperative and postoperative antibiotic prophylaxis and the initial treatment of bacterial keratitis.